key: cord-0301694-99au37tz authors: Farah, Z.; Haddad, N.; Abou El-Naja, H.; Saleh, M.; Mrad, P.; Ghosn, N. title: Effectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults >=75 years- Lebanon, April-May 2021 date: 2022-01-24 journal: nan DOI: 10.1101/2022.01.19.22269514 sha: bb3e63452492f83862f640fea15856974982fc5e doc_id: 301694 cord_uid: 99au37tz Introduction In Lebanon, the nationwide vaccination against COVID-19 was launched in February-2021 using Pfizer-BioNTech vaccine and prioritizing elderly, persons with comorbidities and healthcare workers. Our study aims to estimate the post-introduction vaccine effectiveness (VE) of Pfizer-BioNTech in preventing COVID-19 hospitalization among [≥]75 years in Lebanon. Methods A case-control study design was used. Cases were Lebanese, [≥]75 years and hospitalized with positive PCR result during April-May 2021. Cases were randomly selected from the COVID-19 database of the Epidemiological Surveillance Unit(ESU) at the Ministry of Public Health(MOPH). Each case was matched by age and locality to 2 controls. Controls were hospitalized, non-COVID-19 patients with negative PCR result, randomly selected from the MOPH hospital admission database. VE was calculated for fully and partially vaccinated, using multivariate conditional logistic regression analyses. Results 345 cases and 814 controls were recruited. Half were females, with a mean age of 83 years. 14 cases(5%) and 143 controls(22%) were fully vaccinated. Univariate analysis showed significant association with: gender, month of confirmation/admission, general health, chronic medical conditions, main income source and living arrangement. After adjusting for month of admission and gender, multivariate analysis yielded a VE of 82% (95%CI = 69%-90%) against COVID-19 associated hospitalization for those fully vaccinated and 53% (95%CI = 23%-71%) for those partially vaccinated (<14 days of first or within 14 days of second dose). Conclusions Our study showed that Pfizer-BioNTech vaccine is effective in reducing risk for COVID-19-associated hospitalization in Lebanese elderly([≥]75 years). Additional studies are warranted to explore vaccine effectiveness in reducing hospitalization in younger age groups, as well as in reducing covid-19 infections. Since its emergence in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has taken a tremendous toll on the population worldwide. By 4 May 2021, there have been over 153 million cases and 3.2 million deaths globally from COVID-19 (1) . The implemented non-pharmacological interventions affected the daily lives of billions around the world, resulting in devastating socio-economic repercussions -the biggest challenge that humanity ever faced since World War II (2) . In response to this pandemic, considerable efforts were put globally into developing effective and safe drugs and vaccines against SARS-CoV-2(3). Candidate vaccines were introduced with differing indications, contra-indications and adverse events -each with a specific efficacy in preventing SARS-CoV-2 infection, severe outcomes, and death (4) . Hence, it is of a paramount importance to evaluate the post-introduction effectiveness of the approved and (7) . Pfizer-BioNTech vaccine was used for residents aged 75 and above with a time interval of 21 days between the 2 doses and a coverage of 37% for 2 doses, as of 6 May 2021. As the nationwide vaccination progresses, it is vital to study the vaccine effectiveness in the community as emphasized in the NDVP. Particularly, the national plan mentions the role of the Epidemiological Surveillance Unit(ESU) in studying vaccine effectiveness in order to guide vaccination policies and Public Health and Social Measures (6) . Hence, our study aimed to estimate the post-introduction effectiveness of Pfizer-BioNTech COVID-19 vaccine against COVID-19 hospitalization among Lebanese adults ≥ 75 years. A case-control (CC) study design was conducted using structured questionnaires conducted via phone call interviews (10) . Our sample size was calculated using the precision method with 90% vaccine effectiveness for full vaccination and 40% vaccine coverage, a ±5% precision and a type 1 error of 0.05. A minimum sample size of 318 cases and 636 controls was needed (8) . The minimal sample size was multiplied by 50% to account for non-response and refusals. Proportionate matching with 1:2 cases to control ratio was conducted according to age group ([75-85[; [85-95) ) and locality (governorate) of residence. The COVID-19 surveillance database of the ESU-MOPH was screened to select confirmed cases reported as Lebanese, ≥ 75 years, hospitalized and diagnosed with COVID-19 by Real Time-Polymerase Chain Reaction between April and May 2021. A random sample of 742 cases was drawn from the selected sampling frame and contacted to verify whether they meet our study inclusion criteria. Cases not meeting one of the inclusion criteria were discarded from our analysis. Controls were selected randomly from the MOPH hospital admission database(of uninsured individuals covered by the MOPH) which comprises around 50% of all hospitalizations in Lebanon (9) . The selected controls were Lebanese, ≥ 75 years old and hospitalized between April and May 2021 with admission diagnosis related to all International Classification of Diseases (ICD-10) chapters excluding the COVID19 code. During our study period, any hospitalization due to causes other than COVID-19 required a negative RT-PCR prior to admission, so it was assumed that the negative status of controls is ascertained. Controls were later excluded if the investigation showed they do not meet one of our study inclusion criteria. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. in the logistic regression model, the "change-in-estimate" approach was used (8) . Covariates whose adjustment changed the crude odds ratio by ≥ 5% were included in the final models. VE was estimated using conditional logistic regression following the below formula(8): VE= (1 -matched, adjusted odds ratio for vaccination) x 100% The 95% Confidence Intervals(CIs) of VE were calculated as 1 − CI OR , where CI OR is the confidence interval of the odds ratio estimates. The study was approved by the Institutional Review board of the Rafik Hariri University Hospital. Informed consent was obtained from study subjects prior to participation. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.19.22269514 doi: medRxiv preprint Between April 1 st and May 31 st 2021, 742 cases and 1,561 controls were contacted for the study. However, due to either being excluded for not fitting case/control definition(34%; 23%), no reply(16%; 20%) or refusal to participate(4%; 5%), the retained number of participants was 345 cases to 814 matched controls( Figure 1 ). The mean age of participating cases and controls was 83.1±5.6 and 82.8 ±5.7 years, respectively. The highest proportion of cases and controls resided in Mount-Lebanon governorate (37%; 39%). Cases had an equal proportion of females and males (50%); however, the control group had a significantly higher proportion of females (57%) (P=.03) ( Table 1) . Concerning household arrangement, cases had a greater number of rooms (3.4±1.4) compared to controls (3.0±1.2) and a higher number of household members (2.4±1.7) compared to controls (2.0±1.9) (P <.001). Most cases and controls (87%; 76%) lived with family members. No significant differences were noted for the crowding index between our comparison groups (P=.64) ( Table 1) . For the vast majority in both groups, family support was the main source of income. However, cases (11%) had more retirement pensions than controls (2%) ( Table 1) . Cases (54%, n= 184) were significantly more likely than controls (32%, n=233) to perform calculations without difficulty. They were also more likely to read and write without difficulty (49% of cases as compared to 33% among controls, P<.001). On the other hand, the proportion of subjects reporting inability to read and write was higher among controls (43%, n=329) than cases (27%, n=92) ( Table 1 ). The general health status of the cases and controls in the 12 months prior to admission was also significantly different (P<.001) and was mostly good (44% for cases and 36% for controls) followed by fair health status (26% cases and 32% for controls). 41% of cases reported no difficulty walking, climbing up and down stairs prior to admission, while 34% of controls did not have the ability to conduct this task ( Table 1) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Majority of cases and controls had at least one underlying condition (85%; 92%) (P=.001). The underlying conditions reported for both cases and controls were mostly hypertension (70%; 76%) followed by heart diseases (50%;66%), and diabetes (43%; 47%) respectively (Table 1) . As for hospitalization information, the mean duration of hospital stay was significantly higher among cases (11.1±9.3 days) compared to controls (6.0±7.0 days). In particular, the length of stay was mostly >7 days for cases (53%) while 3-7 days for controls (60%). Majority of cases required ICU admission (67%) with a longer duration of stay (8.5±7.9 days) while 25% of controls were admitted to ICU (P<.001) ( Table 2) . Furthermore, cases were significantly more likely than controls to require oxygen therapy (90%) and intubation (46%) (P<0.001). Death upon discharge was significantly higher among cases (52%) compared to controls (10%) (P<0.001). Among cases, the majority were due to COVID-19(93%) ( Table 2) . Of note, no change in the above results was found when restricting the Univariate analysis to participants with complete vaccination data. Majority of cases and controls reported zero dose of vaccination (81%; 63%), 13% of cases reported having received one dose of vaccine compared to 11% for controls, and 5% of cases reported having two doses compared to 27% of controls. Majority of cases and controls reported no side effects following 1 st dose (66%; 82%) and second dose (67%; 81%) respectively (P=.002 and .13 respectively) ( Table 3) . Taking fully vaccinated individuals as 14 days after second dose, 14 cases (4%) and 143 controls (21%) were fully vaccinated and the crude OR was 0.16 (95%CI = 0.09-0.28). After adjusting for month of admission and gender, multivariate analysis yielded an adjusted OR of 0.18 and a VE of 82% (95%CI = 69%-90%) ( Table 3) . For those partially vaccinated, the crude OR was 0.49 (95%CI = 0.30-0.79). After adjusting for month of admission, the adjusted OR was 0.47 and the vaccine effectiveness was 53% (95%CI = 23%-71%) ( Table 4) . On the other hand, there was no significant effect for receiving the first dose of the vaccine within 14 days of confirmation/admission (adjusted OR = 1.09 and 95% CI = 0.63-1.87). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. However, our findings are lower than the VE reported in some studies assessing the effectiveness of mRNA vaccines against COVID19 hospitalization mainly two studies All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (17, 18) The difference between the study results could be due mostly to the mean age group of this study which is around 83 years, higher in comparison to the other studies. Moreover, the fact that some of these studies were assessing a combination of mRNA vaccines, not only the (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.19.22269514 doi: medRxiv preprint limited their exposure to their bubble, hence decreasing the risk of exposure to infection during the pandemic. Any of these directions might have biased our VE estimates. Additionally, majority of cases and controls reported having zero dose of vaccination (90%; 64%) at the time of study, which can be explained by the timeline of vaccine rollout in the country that started in mid-February and that faced delays in initiation due to interruptions in receiving vaccine batches into the country. On the other hand, important results to be highlighted are the severity of illness of COVID-19 associated hospitalization as compared to non-COVID-19 hospitalizations. This study clearly reveals that although COVID-19 hospitalized patients subjectively have a better rating for their general health status, their prognosis is much worse than non-COVID-19 patients hospitalized with longer durations of stay, significantly higher need for intensive care, oxygen therapy and intubation, and ultimately death. As vaccination may provide false sense of security, our findings highlight the importance of adhering to public health measures to avoid COVID-19 associated hospitalization where vaccinated individuals are still advised to continue practicing hand hygiene, physical distancing, and mask wearing (20) . The study findings are subject to some limitations. First, The MOPH admission database, from which controls were sampled, is not inclusive of the total target population as it covers hospitalization of citizens who are uninsured and who usually belong to the most deprived segments of the population, such as seasonal workers, farmers, retired and unemployed persons, thus on average an older and poorer population (9) . Additionally, vaccine effectiveness estimates might be confounded by certain unmeasured behaviors like adherence to non-pharmaceutical interventions, including mask use or recent attendance of gatherings in addition to some variables like socioeconomic status and prior SARS-COV-2 infection. This might have affected our results as uncontrolled confounders might lead to differences in vaccine uptake, exposure to infection, and development of severe disease implications. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. *Adjusted for month of confirmation/admission and gender **Adjusted for month of confirmation/admission All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.19.22269514 doi: medRxiv preprint World Health Organization. WHO Coronavirus (COVID-19) Dashboard Coronavirus: Greatest test since World War Two, says UN chief -BBC News A systematic review of SARS-CoV-2 vaccine candidates COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines World Health Organization. COVID-19 Daily Brief. Lebanon, country office Ministry of Public Health. Lebanon National Deployment and Vaccination Plan for COVID-19 Vaccines Impact Open Data: Vaccine Statistics World Health Organization. Evaluation of COVID-19 vaccine effectiveness: interim guidance World Health Organization Health System and Reform In Lebanon -2003 Monitoring of COVID-19 Infection In Lebanon-Daily report Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥ 65 Years -United States Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions -United States Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study Replacement of the Alpha variant of SARS-CoV-2 by the Delta variant in Lebanon between COVID-19 Vaccination The authors would like to acknowledge the efforts of the ESU teams in helping in data collection and would like to thank all reporting sites for their continuous collaboration with the MOPH.